🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

525 results for “Teva” Clear

  1. PACLITAXEL , Trodelvy 200 mg powder for concentrate for solution for infusion, Doxorubicin Teva 2 mg/ml Concentrate for Solution for Infusion

    Gilead Sciences International Limited

    Recurrent or Persistent Endometrial Cancer

    phase 3 small molecule active

    1 trial

  2. PROVIGIL 200 mg

    Teva Pharma GmbH

    Chronic Shift Work Sleep Disorder

    phase 3 small molecule completed

    1 trial

  3. Paclitaxel 6mg/ml Concentrate for Solution for Infusion, Doxorubicin Teva 2 mg/ml Concentrate for Solution for Infusion, Fluorouracil 50 mg/ml Solution for Injection or Infusion, Tamoxifen 20 mg Tablets, Epirubicin 2 mg/ml Solution for Injection, Endoxana Injection 500 mg Powder for Solution for Injection, Anastrozole 1 mg film-coated tablets, TAXOTERE 20 mg/0.5 ml concentrate and solvent for solution for infusion

    Cancer Prevention Pharma (Ireland) Limited

    Patients with 1-3 positive Nodes, Hormone Receptor-Positive and Her2-Negative Breast Cancer with recurrence Score (RS) of 25 or Less

    phase 3 small molecule active

    1 trial

  4. Paclitaxel Aurobindo 6 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Ipilimumab, Cisplatin Teva® 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, CARBOPLATIN, ALIMTA 500 mg powder for concentrate for solution for infusion, Cisplatin NeoCorp 1 mg/ml - Konzentrat zur Herstellung einer Infusionslösung, TAXOL 6 mg/ml, concentrato per soluzione per infusione., OPDIVO 10 mg/mL concentrate for solution for infusion., Paclitaxel-GRY® 6 mg/ml Konzentrat zur Herstellung einer Infusionslösung, CISPL

    Bristol-Myers Squibb / Pfizer EEIG

    Stage IV Non-Small Cell Lung Cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  5. Paclitaxel, Bevacizumab, liposomal doxorubicin, Capecitabine

    Teva Pharma GmbH

    Human Epidermal Growth Factor 2 Negative Carcinoma of Breast

    phase 3 small molecule completed

    1 trial

  6. Pemetrexed Accord 25 mg/ml concentrate for solution for infusion, TAGRISSO 40 mg film-coated tablets, Cisplatine Teva 1 mg/ml concentraat voor oplossing voor infusie., Cisplatin Teva® 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, CARBO-cell® 10 mg/ml Infusionslösung, Konzentrat zur Herstellung einer Infusionslösung, ALIMTA 100 mg powder for concentrate for solution for infusion, Cisplatine Teva 1 mg/ml concentraat voor oplossing voor infusie., Carboplatin Kabi 10 mg/ml Konzentrat zur Herstellung

    AstraZeneca AB

    Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  7. Placebo MDPI

    Teva Pharma GmbH

    Asthma

    phase 3 small molecule completed

    3 trials

  8. Placebo Nasal Aerosol

    Teva Pharma GmbH

    Perennial Allergic Rhinitis

    phase 3 small molecule completed

    1 trial

  9. Placebo Spiromax

    Teva Pharma GmbH

    Asthma

    phase 3 small molecule terminated

    1 trial

  10. Rasagiline

    Teva Pharma GmbH

    Progressive Supranuclear Palsy

    phase 3 small molecule terminated

    1 trial

  11. Reslizumab

    Teva Pharma GmbH

    Eosinophilic Asthma

    phase 3 small molecule completed

    5 trials

  12. Reslizumab

    Teva Pharma GmbH

    Severe Persistent Asthma

    phase 3 mab completed

    1 trial

  13. SD-809

    Teva Pharma GmbH

    Chorea

    phase 3 small molecule completed

    1 trial

  14. SD-809

    Teva Pharma GmbH

    Tardive Dyskinesia

    phase 3 small molecule completed

    3 trials

  15. SD-809

    Teva Pharma GmbH

    Chorea Associated With Huntington Disease

    phase 3 small molecule completed

    1 trial

  16. Seasonale (levonorgestrel and ethinyl estradiol)

    Teva Pharma GmbH

    Osteopenia

    phase 3 small molecule terminated

    1 trial

  17. Seasonale [levonorgestrel (LNG)/ethinyl estradiol (EE)]

    Teva Pharma GmbH

    Healthy

    phase 3 small molecule completed

    1 trial

  18. StemEx®

    Teva Pharma GmbH

    Hematologic Malignancies

    phase 3 small molecule completed

    1 trial

  19. Synthetic Conjugated estrogens, B

    Teva Pharma GmbH

    Menopause

    phase 3 small molecule completed

    1 trial

  20. TEV-45779

    Teva Pharma GmbH

    Chronic Urticaria

    phase 3 other completed

    1 trial

  21. TEV-50717

    Teva Pharma GmbH

    Cerebral Palsy, Dyskinetic

    phase 3 small molecule terminated

    2 trials

  22. TEV-50717

    Teva Pharma GmbH

    Tourette Syndrome

    phase 3 small molecule terminated

    3 trials

  23. TEV-56248

    Teva Pharma GmbH

    Asthma

    phase 3 small molecule active

    2 trials

  24. TV-1106

    Teva Pharma GmbH

    Growth Hormone-Deficiency

    phase 3 small molecule terminated

    4 trials

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources